Monday, March 21, 2011

FDA: Alzheimer's, Amyvid (florbetapir)

From MedPage Today:

FDA Puts Early Alzheimer's Test on Hold
By Peggy Peck, Executive Editor
MedPage Today
Published: March 18, 2011


"The FDA will not approve the novel contrast agent, florbetapir -- widely touted as a breakthrough for early diagnosis of Alzheimer's disease -- until manufacturer Eli Lilly puts a training program in place, the company announced."


Read the article.

1 comment:

Alexandra said...


I am an editor at The Nerve, BU's neuroscience magazine and blog. Since we're just starting up, we are looking to create a following of readers interested in the mind and brain. Could you please add a link to our site on your blog? We'd be glad to do the same for you.

The Nerve Editors